Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
8.26
-0.27 (-3.17%)
At close: Nov 7, 2025, 4:00 PM EST
8.24
-0.02 (-0.24%)
After-hours: Nov 7, 2025, 7:51 PM EST
Biohaven Employees
Biohaven had 256 employees as of December 31, 2024. The number of employees increased by 17 or 7.11% compared to the previous year.
Employees
256
Change (1Y)
17
Growth (1Y)
7.11%
Revenue / Employee
n/a
Profits / Employee
-$2,995,980
Market Cap
873.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BHVN News
- 2 days ago - Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Benzinga
- 3 days ago - Biohaven shares plunge after US FDA declines to approve brain disorder drug - Reuters
- 3 days ago - FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia - PRNewsWire
- 2 months ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVN - GlobeNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven - PRNewsWire
- 2 months ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven - GlobeNewsWire
- 2 months ago - Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025 - Seeking Alpha
- 2 months ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven - PRNewsWire